Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

TFIP11 Inhibitors

TFIP11 inhibitors represent a chemical class targeting the TFIP11 protein, a key factor involved in the regulation of RNA splicing and maturation. TFIP11, also known as "tuftelin-interacting protein 11," plays a pivotal role in ribonucleoprotein particle assembly and pre-mRNA splicing by interacting with spliceosomal components. Specifically, it is a critical factor in the transition of the U4/U6 di-snRNP to U5, a process essential for proper mRNA maturation. The inhibition of TFIP11 disrupts this finely tuned process, leading to aberrations in RNA processing, including mis-splicing, retention of introns, and improper assembly of spliceosomal machinery. TFIP11 inhibitors therefore act by interfering with the key interactions or activities of the TFIP11 protein, which can directly affect RNA homeostasis at a molecular level.

From a structural standpoint, TFIP11 inhibitors are often characterized by their ability to bind to key domains within the TFIP11 protein that are necessary for its interaction with RNA or other spliceosomal components. The specificity of these inhibitors is crucial because TFIP11 is highly conserved and plays an integral role in maintaining cellular RNA integrity. Modulation of TFIP11 function through its inhibitors allows researchers to study the cascading effects of disrupted RNA splicing pathways, providing insight into broader cellular processes, such as RNA transport and degradation. Understanding the chemical features that enable this inhibition, such as the binding affinity to critical protein motifs or interference with post-translational modifications of TFIP11, is essential for advancing knowledge in RNA biology and exploring the broader impact of splicing dysregulation on cellular function.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

Alectinib is a kinase inhibitor that targets the ALK gene fusion protein in non-small cell lung cancer, blocking its signaling and inhibiting tumor growth.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, blocking phosphorylation and downstream signaling, which is crucial in cancer cell proliferation.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib targets multiple kinases, including Raf and VEGFR, to inhibit angiogenesis and block cell proliferation in various cancers.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib is a tyrosine kinase inhibitor that specifically inhibits the BCR-ABL fusion protein, essential in the development of chronic myeloid leukemia (CML).

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Lapatinib inhibits both EGFR and HER2 kinases, hindering their signaling pathways, and is used in breast cancer.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib targets multiple kinases, including BCR-ABL, inhibiting cell proliferation in CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Vemurafenib specifically inhibits BRAF V600E kinase, a common mutation in melanoma, blocking MAPK pathway activation.

Rucaparib

283173-50-2sc-507419
5 mg
$150.00
(0)

Rucaparib is a PARP inhibitor, disrupting DNA repair in cancer cells and leading to their death, particularly effective in BRCA-mutated tumors.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Ibrutinib inhibits BTK kinase, essential for B-cell receptor signaling in B-cell malignancies, including chronic lymphocytic leukemia (CLL).

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

Osimertinib targets EGFR T790M mutations in non-small cell lung cancer (NSCLC), inhibiting aberrant signaling in resistant tumors.